Menu Search
Equities

Pila Pharma AB

5KC:DEU

Pila Pharma AB

Actions
  • Price (EUR)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Pila Pharma AB is a Sweden-based clinical stage pharmaceutical company, active in the biotechnology sector. The Company conducts clinical tests in phase 2 with drugs against type 2 diabetes. The target product is a tablet that is taken orally in an early stage of diabetes to restore the body's insulin production and thereby reduce the patient's blood sugar level. PILA PHARMA's patent-protected product candidate is called XEN-D0501 and is a TRPV1 antagonist, a novel type of oral anti-diabetic agent for treatment of type 2 diabetes. Pila Pharma AB has completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D0501 is well tolerated by people with type 2 diabetes. In addition, the product is expected to have fewer unwanted side effects than alternative forms of treatment.

  • Revenue in SEK (TTM)1.03m
  • Net income in SEK-6.92m
  • Incorporated2014
  • Employees0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.